Fresenius Medical Care AG & Co. KGaA (FME) PT Set at €79.00 by Independent Research

Independent Research set a €79.00 ($91.86) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research report sent to investors on Friday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

FME has been the topic of several other research reports. HSBC set a €87.00 ($101.16) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Wednesday, February 13th. JPMorgan Chase & Co. set a €86.50 ($100.58) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Tuesday, April 30th. UBS Group set a €82.00 ($95.35) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Thursday, May 2nd. Berenberg Bank set a €88.65 ($103.08) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Tuesday, March 5th. Finally, Goldman Sachs Group set a €79.00 ($91.86) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Monday, April 1st. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of €83.96 ($97.62).

Shares of FME opened at €74.44 ($86.56) on Friday. The company has a market cap of $22.62 billion and a P/E ratio of 11.54. Fresenius Medical Care AG & Co. KGaA has a 12-month low of €55.44 ($64.47) and a 12-month high of €91.74 ($106.67). The company has a debt-to-equity ratio of 58.49, a quick ratio of 0.96 and a current ratio of 1.25.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: What is an overbought condition?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.